You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Iodine -131 Anti-B1 Antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult

Terminated
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +9 more
  • Allogeneic Bone Marrow Transplantation
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2021

Lymphoma, Mantle-Cell Trial (Tositumomab and Iodine I 131 Tositumomab followed by CHOP)

Completed
Has Results
  • Lymphoma, Mantle-Cell
  • Tositumomab and Iodine I 131 Tositumomab followed by CHOP
  • (no location specified)
Nov 19, 2019

Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

Not yet recruiting
  • Solid Tumor, Adult
  • +2 more
  • (no location specified)
Dec 14, 2022

Neuroblastoma Trial in Madison, Southampton, London (Nivolumab, Ch14.18/CHO)

Recruiting
  • Neuroblastoma
  • Madison, Wisconsin
  • +2 more
Mar 28, 2022

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

Recruiting
  • Non-Malignant Neoplasm
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 29, 2022

Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNa Trial in Chongqing (Anti-PD-1 antibody, NAs, Peg-IFNa)

Not yet recruiting
  • Chronic Hepatitis b
  • +2 more
  • Anti-PD-1 antibody
  • +2 more
  • Chongqing, Chongqing, China
    The 2nd affiliated Hospital of Chongqing Medical University
Mar 14, 2023

Cancer Trial (Antibody-Drug Conjugate)

Not yet recruiting
  • Cancer
  • Antibody-Drug Conjugate
  • (no location specified)
Aug 23, 2023

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Chronic Hepatitis b, Anti-PD-1 Antibody Trial in Chongqing (Anti-PD-1 antibody, NAs)

Not yet recruiting
  • Chronic Hepatitis b
  • Anti-PD-1 Antibody
  • Anti-PD-1 antibody
  • NAs
  • Chongqing, Chongqing, China
    The 2nd affiliated Hospital of Chongqing Medical University
Mar 3, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial (BN301)

Not yet recruiting
  • B-cell Lymphoma
  • +4 more
  • (no location specified)
Nov 9, 2022

Relapsed or Refractory DLBCL Trial (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Not yet recruiting
  • Relapsed or Refractory DLBCL
  • Anti-PD-1 Antibody Plus Chidamide and Rituximab
  • (no location specified)
Apr 6, 2022

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

Advanced/Metastatic Solid Tumors Trial in Australia, United States (ADG116, ADG106, anti PD1 drug)

Recruiting
  • Advanced/Metastatic Solid Tumors
  • San Antonio, Texas
  • +3 more
Jan 26, 2022

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Healthy Trial in Leuven (REGN15160 (IV), Matching Placebo (IV), REGN15160 (SC))

Active, not recruiting
  • Healthy
  • REGN15160 (IV)
  • +3 more
  • Leuven, Belgium
    Regeneron Study Site
Jan 6, 2023

NSCLC, Pancreatic Cancer, Locally Advanced Solid Tumor Trial in Sydney (HMBD-001, Docetaxel, Nab-paclitaxel)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 16, 2023

MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

Not yet recruiting
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • MSI-H/dMMR Gastric Cancer
  • (no location specified)
Oct 30, 2023

Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

Recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • Duarte, California
  • +3 more
Jan 12, 2023

Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

Completed
  • Neoplasm
  • Chuo-Ku, Japan
  • +1 more
Nov 3, 2022

Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer Trial (HFB200603, Tislelizumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • +4 more
  • (no location specified)
Mar 15, 2023

Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer Trial in Baltimore (AG-01 Compound)

Recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • AG-01 Compound
  • Baltimore, Maryland
    University of Maryland Greenebaum Comprehensive Cancer Center
Nov 16, 2022

Multiple Myeloma Trial in Canton (STI-6129)

Recruiting
  • Multiple Myeloma
  • STI-6129
  • Canton, Ohio
    Gabrail Cancer Center
Jun 29, 2022